GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alligator Bioscience AB (STU:7AL) » Definitions » Debt-to-Asset

Alligator Bioscience AB (STU:7AL) Debt-to-Asset : 0.16 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Alligator Bioscience AB Debt-to-Asset?

Alligator Bioscience AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.76 Mil. Alligator Bioscience AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.48 Mil. Alligator Bioscience AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €7.76 Mil. Alligator Bioscience AB's debt to asset for the quarter that ended in Mar. 2024 was 0.16.


Alligator Bioscience AB Debt-to-Asset Historical Data

The historical data trend for Alligator Bioscience AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alligator Bioscience AB Debt-to-Asset Chart

Alligator Bioscience AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.08 0.03 0.14 0.14

Alligator Bioscience AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.09 0.10 0.14 0.16

Competitive Comparison of Alligator Bioscience AB's Debt-to-Asset

For the Biotechnology subindustry, Alligator Bioscience AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alligator Bioscience AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's Debt-to-Asset falls into.



Alligator Bioscience AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Alligator Bioscience AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Alligator Bioscience AB's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alligator Bioscience AB  (STU:7AL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Alligator Bioscience AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Alligator Bioscience AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Alligator Bioscience AB (STU:7AL) Business Description

Traded in Other Exchanges
Address
Scheelevagen 2, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a research-based biotechnology company that develops immune activating antibody drugs for tumor-directed immunotherapy. It is engaged in the development of immunotherapies for the treatment of cancer Its products are ADC-1013, ATOR-1015, and ATOR-1016.

Alligator Bioscience AB (STU:7AL) Headlines

No Headlines